Janke Dittmer joined Gilde in 2011 as a Partner. He led Gilde’s investment in Definiens (acquired by AZ), Sapiens (acquired by Medtronic), Volta Medical, Big Health, FIRE1, Lumeon and Nyxoah (IPO on NASDAQ) and was involved in several other investments including Spire Health, Withings, NightBalance and Stat Dx. He currently represents Gilde on the board of Volta Medical, Big Health, FIRE1 and Lumeon. He served on the supervisory board of Definiens and Sapiens until trade sale and as Vice-chairman of Nyxoah until NASDAQ IPO.
Prior to joining, he was a Venture General Manager and Head of Business Development & Strategy within Philips’ Corporate Venturing unit in Healthcare. On top of shaping the strategy, he was responsible for selecting new investment opportunities. He also started and lead two ventures in the fields of cardiology and sepsis.
He served as an Engagement Manager at McKinsey & Company advising leading High Tech companies on strategies for growth and strategic marketing.
Prior to this, he cofounded a Nanotech company in the Silicon Valley after serving as a Fellow at the Lawrence Berkeley National Lab. He earned a PhD in Physics from the University of Cambridge in the UK and was a Post-Doc in Nanotechnology at the University of California, Berkeley.
He is a founder and former healthcare chairman of the International Venture Club, serves on the VC council of Invest Europe and has advised the European Commission on innovation policy.
He is a German citizen based in Gilde’s Utrecht office. At Gilde Healthcare he is focusing on Digital and Home Health, MedTech, Diagnostics and Lifescience Tools investments.